Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 6/20 | 0.38 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.37 |
| ▸ | CFTR | P13569 | 4/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | LITAF | Q99732 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31000115 | 0.88 | CFTR (0.40) | ALKDNMT3ACFTRNSD2CCNT1 | |
| SCHEMBL31639293 | 0.83 | TRPV3 (0.37) | ALKDNMT3ANSD2CCNT1CDK9 | |
| SCHEMBL31739613 | 0.83 | ALK (0.35) | ALKDNMT3ACFTRNTRK1NSD2 | |
| SCHEMBL27327760 | 0.82 | FLT3 (0.40) | — | |
| SCHEMBL27330374 | 0.82 | FLT3 (0.40) | — | |
| SCHEMBL30716642 | 0.81 | EIF2AK4 (0.38) | NTRK1TRPV3GPR119 | |
| SCHEMBL30716643 | 0.81 | EIF2AK4 (0.38) | NTRK1TRPV3GPR119 | |
| SCHEMBL31739827 | 0.81 | FLT3 (0.35) | TNF | |
| SCHEMBL27329570 | 0.81 | FLT3 (0.35) | TNF | |
| SCHEMBL27327086 | 0.81 | FLT3 (0.35) | TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368648-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4540248-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | Children's Hospital Medical Center (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023245123-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368648-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK1, IRAK2 | ALK 128/4885DNMT3A 27/4885CFTR 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.